Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.53 |
| ▸ | TACR1 | P25103 | 10/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280585 | 0.86 | IDO1 (0.63) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL8281936 | 0.80 | ALDH1A1 (0.35) | IDO1TSHRMAPK1 | |
| SCHEMBL2130249 | 0.80 | ALDH1A1 (0.35) | IDO1TSHRMAPK1 | |
| SCHEMBL16956459 | 0.79 | IDO1 (0.50) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL25112281 | 0.79 | IDO1 (0.50) | IDO1TACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL10959537 | 0.79 | IDO1 (0.44) | IDO1TACR1MAOBTSHRMAPK1 | |
| SCHEMBL29467109 | 0.79 | IDO1 (0.44) | IDO1TACR1MAOBTSHRMAPK1 | |
| SCHEMBL27734414 | 0.78 | IDO1 (0.46) | IDO1TACR1MAOB | |
| SCHEMBL5426047 | 0.78 | IDO1 (0.39) | IDO1TACR1MAOBCACNA1FCACNA1D | |
| SCHEMBL864911 | 0.78 | IDO1 (0.47) | IDO1MAOBTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | claimed |
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IDO1 1457/4885TACR1 1079/4885MAOB 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.